CD274 and neoplasm: Current consensus on the most effective population-based screening criteria for PD-1 benefit is summarized as follows: high tumor mutational load (TMB), high microsatellite instability (MSI-H), defective mismatch repair (dMMR) and high PD-L1 expression with tumor infiltrating lymphocytes (TIL).